Patient-derived xenograft (PDX) models, in which tumor tissues from patients are implanted
into immunocompromised or humanized mice, have shown superiority in recapitulating the …

Neuroblastoma is the most common extracranial solid tumor in children. One subset, high-
risk neuroblastoma, is very difficult to treat and requires multi-modal therapy. Intensification …

Neuroblastomas harbor ALK aberrations clinically resistant to crizotinib yet sensitive pre-
clinically to the third-generation ALK inhibitor lorlatinib. We conducted a first-in-child study …

ABSTRACT A vast array of oncogenic variants has been identified for anaplastic lymphoma
kinase (ALK). Therefore, there is a need to better understand the role of ALK in cancer …

Purpose: Anaplastic lymphoma kinase (ALK) aberrations are a promising target for patients
with neuroblastoma. We assessed the activity of first-generation ALK inhibitor crizotinib in …

Selection of the best tumor antigen is critical for the therapeutic success of chimeric antigen
receptor (CAR) T cells in hematologic malignancies and solid tumors. The anaplastic …

Neuroblastoma (NB) is the most common and deadly solid tumour in children. Despite the
development of new treatment options for high-risk NB, over half of patients relapse and five …

Activating point mutations in Anaplastic Lymphoma Kinase (ALK) have positioned ALK as
the only mutated oncogene tractable for targeted therapy in neuroblastoma. Cells with these …

Neuroblastoma evolution, heterogeneity, and resistance remain inadequately defined,
suggesting a role for circulating tumor DNA (ctDNA) sequencing. To define the utility of …

Abstract The first (2017) and sixth (2021) multistakeholder Paediatric Strategy Forums
focused on anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies. ALK is …